

Haematologica
HAEMATOL/2020/252916
Version 1

ABL-class fusion positive acute lymphoblastic leukemia: ABL-e to cure
ALL?

Thai Hoa Tran and Stephen Hunger

Disclosures: Dr. Hunger has received consulting fees from Novartis and honoraria from Amgen, and owns stock in Amgen.

Contributions: Drs. Tran and Hunger wrote the editorial together and provided final approval of the submitted version.